Faculty Profiles - TAKEMOTO Mami

Papers - TAKEMOTO Mami

Division display 21 - 40 of about 253 ／ All the affair displays >>

Human Cord Blood-Endothelial Progenitor Cells Alleviate Intimal Hyperplasia of Arterial Damage in a Rat Stroke Model. International journal

Hongming Sun, Ryuta Morihara, Tian Feng, Zhihong Bian, Haibo Yu, Xiao Hu, Xinran Hu, Yuting Bian, Ryo Sasaki, Yusuke Fukui, Mami Takemoto, Taijun Yunoki, Yumiko Nakano, Koji Abe, Toru Yamashita

Cell transplantation 32 9636897231193069 - 9636897231193069 2023

Language：English Publishing type：Research paper (scientific journal)

Human cord blood-endothelial progenitor cells (hCB-EPCs) isolated from the human umbilical cord can be used to repair damaged arteries. In this study, we used an animal model with pathological changes that mimics artery wall damage caused by stent retrievers in humans. We injected hCB-EPCs to investigate their effect on endothelial hyperplasia and dysfunction during intimal repair. Four groups were established based on the length of reperfusion (3 and 28 days), as well as the presence or absence of hCB-EPC therapy. Damage to the internal carotid artery was evaluated by hematoxylin-eosin and immunohistochemical staining. Stroke volume was not significantly different between non-EPC and EPC groups although EPC treatment alleviated intimal hyperplasia 28 days after intimal damage. Vascular endothelial growth factor (VEGF) and eNOS expression were significantly higher in the EPC-treated group than in the non-EPC group 3 days after intimal damage. In addition, MMP9 and 4HNE expression in the EPC-treated group was significantly lower than in the non-EPC group. Ultimately, this study found that venous transplantation of hCB-EPCs could inhibit neointimal hyperplasia, alleviate endothelial dysfunction, suppress intimal inflammation, and reduce oxidative stress during healing of intimal damage.

DOI： 10.1177/09636897231193069

PubMed

researchmap

Tocovid Attenuated Oxidative Stress and Cognitive Decline by Inhibiting Amyloid-β-Induced NOX2 Activation in Alzheimer's Disease Mice. International journal

Zhihong Bian, Haibo Yu, Xinran Hu, Yuting Bian, Hongming Sun, Koh Tadokoro, Mami Takemoto, Taijun Yunoki, Yumiko Nakano, Yusuke Fukui, Ryuta Morihara, Koji Abe, Toru Yamashita

Journal of Alzheimer's disease : JAD 2022.12

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: NADPH oxidase 2 (NOX2) is an important source of reactive oxygen species (ROS). Activated NOX2 may contribute to Alzheimer's disease (AD). Our previous studies showed that a novel vitamin E mixture, Tocovid, had potential neuroprotective effects in a stroke mice model and an AD cell model. OBJECTIVE: The aim of this study was two-fold: to assess whether long-term Tocovid treatment can regulate NOX2, and the therapeutic effects of long-term administration of Tocovid to an AD mice model. METHODS: Therapeutic effects of long-term administration of Tocovid (200 mg/kg /day) on an Aβ-overexpressed transgenic AD mice model (APP23, n = 8) was investigated. The therapeutic effect of Tocovid in 16-month-old mice compared with the no-treatment APP23 group (n = 9) was assessed. RESULTS: Tocovid treatment strongly improved motor and memory deficits of APP23 mice by attenuating NOX2 expression, oxidative stress, neuroinflammation, neurovascular unit dysfunction, synaptic alteration, and Aβ deposition after 16 months. CONCLUSION: These findings suggest that NOX2 is a potential target in AD pathology. Long-term administration of Tocovid may be a promising candidate for AD treatment.

DOI： 10.3233/JAD-220761

PubMed

researchmap

Actual Telemedicine Needs of Japanese Patients with Neurological Disorders in the COVID-19 Pandemic.

Ryo Sasaki, Taijun Yunoki, Yumiko Nakano, Yusuke Fukui, Mami Takemoto, Ryuta Morihara, Koji Abe, Toru Yamashita

Internal medicine (Tokyo, Japan) 62 ( 3 ) 365 - 371 2022.11

Language：English Publishing type：Research paper (scientific journal)

Objective During the coronavirus disease 2019 (COVID-19) pandemic, many social activities have moved online using applications for digital devices (e.g. computers, smartphones). We investigated the needs of telemedicine and trends in medical status and social care situations of Japanese patients with neurological disorders in order to estimate their affinity for an online telemedicine application. Methods We designed an original questionnaire for the present study that asked participants what problems they had with hospital visits, how the COVID-19 pandemic had affected their lives, and whether or not they would like to receive telemedicine. Patients The present study included volunteer caregivers, participants with Parkinson's disease (PD), epilepsy, stroke, dementia, immune-mediated neurological disease (IMMD), spinocerebellar degeneration (SCD), amyotrophic lateral sclerosis (ALS), headache, myopathy, and other neurological diseases from Okayama University Hospital. Results A total of 29.6% of patients wanted to use telemedicine. Patients with headaches (60.0%) and epilepsy (38.1%) were more likely to want to use telemedicine than patients with PD (17.8%) or stroke (19.0%). Almost 90% of patients had access to a digital device, and there was no association between favoring telemedicine, ownership of a digital device, hospital visiting time, or waiting time at the hospital, although age was associated with motivation to telemedicine use (52.6 vs. 62.2 years old, p <0.001*). Conclusion We can contribute to the management of the COVID-19 pandemic and the medical economy by promoting telemedicine, especially for young patients with headaches or epilepsy.

DOI： 10.2169/internalmedicine.9702-22

PubMed

researchmap

Novel <scp> ABCD1 </scp> mutation detected in a symptomatic female carrier of adrenoleukodystrophy

Yumiko Nakano, Yuki Taira, Ryo Sasaki, Koh Tadokoro, Taijun Yunoki, Emi Nomura, Yusuke Fukui, Mami Takemoto, Ryuta Morihara, Nobuyuki Shimozawa, Toru Yamashita

Neurology and Clinical Neuroscience 2022.10

Anti-oxidative and the anti-inflammatory response of carnosine in a mice stroke model(和訳中)

胡欣冉, 阿部康二, 福井裕介, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 山下徹

脳循環代謝 34 ( 1 ) 153 - 153 2022.10

視線計測計を用いた認知機能障害の早期スクリーニング

福井裕介, 田所功, 野村恵美, 涌谷陽介, 高尾芳樹, 東靖人, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 150 - 150 2022.10

Efficiency of Plasmalogen in a Mouse Model of Alzheimer's Disease with Cerebral Hypoperfusion(和訳中)

Zhai Yun, Feng Tian, 胡欣冉, 福井裕介, 卞之宏, Bian Yuting, 孫洪銘, 武本麻美, 柚木太淳, 中野由美子, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 160 - 160 2022.10

Rivaroxaban attenuated amyloid pathology and neuroinflammation by inhibiting PAR-1/PAR-2 in AD mice(和訳中)

Bian Zhihong, Liu Xia, Yu Haibo, Hu Xinran, Bian Yuting, Sun Hongming, 田所功, 武本麻美, 柚木太淳, 中野由美子, 福井裕介, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 158 - 158 2022.10

腺性自己免疫症候群3型に抗MOG抗体関連急性脊髄炎を合併した一例

柚木太淳, 中野由美子, 中田有美, 佐々木諒, 田所功, 武本麻美, 森原隆太, 山下徹

臨床神経学 62 ( 10 ) 824 - 824 2022.10

髄液検体から診断に至った再発性の抗MOG抗体関連疾患の2症例

中野由美子, 佐々木諒, 中田有美, 田所功, 柚木太淳, 野村恵美, 武本麻美, 森原隆太, 山下徹

臨床神経学 62 ( 10 ) 824 - 824 2022.10

腺性自己免疫症候群3型に抗MOG抗体関連急性脊髄炎を合併した一例

柚木太淳, 中野由美子, 中田有美, 佐々木諒, 田所功, 武本麻美, 森原隆太, 山下徹

臨床神経学 62 ( 10 ) 824 - 824 2022.10

視線計測計Gazefinderを用いた認知症診断の可能性

田所功, 福井裕介, 野村恵美, 涌谷陽介, 高尾芳樹, 東靖人, 小坂田陽介, 松本菜見子, 佐々木諒, 武本麻美, 菱川望, 森原隆太, 阿部康二, 山下徹

臨床神経学 62 ( Suppl. ) S323 - S323 2022.10

髄液検体から診断に至った再発性の抗MOG抗体関連疾患の2症例

中野由美子, 佐々木諒, 中田有美, 田所功, 柚木太淳, 野村恵美, 武本麻美, 森原隆太, 山下徹

臨床神経学 62 ( 10 ) 824 - 824 2022.10

視線計測計を用いた認知機能障害の早期スクリーニング

福井裕介, 田所功, 野村恵美, 涌谷陽介, 高尾芳樹, 東靖人, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 150 - 150 2022.10

脳梗塞モデルマウスにおけるカルノシンの抗酸化作用と抗炎症作用(Anti-oxidative and the anti-inflammatory response of carnosine in a mice stroke model)

胡欣冉, 阿部康二, 福井裕介, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 山下徹

脳循環代謝 34 ( 1 ) 153 - 153 2022.10

RivaroxabanはADマウスのPAR-1/PAR-2阻害によりアミロイド病態と神経炎症を抑制する(Rivaroxaban attenuated amyloid pathology and neuroinflammation by inhibiting PAR-1/PAR-2 in AD mice)

Bian Zhihong, Liu Xia, Yu Haibo, Hu Xinran, Bian Yuting, Sun Hongming, 田所功, 武本麻美, 柚木太淳, 中野由美子, 福井裕介, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 158 - 158 2022.10

脳低灌流を伴うアルツハイマー病モデルマウスにおけるプラズマローゲンの有効性(Efficiency of Plasmalogen in a Mouse Model of Alzheimer's Disease with Cerebral Hypoperfusion)

Zhai Yun, Feng Tian, 胡欣冉, 福井裕介, 卞之宏, Bian Yuting, 孫洪銘, 武本麻美, 柚木太淳, 中野由美子, 森原隆太, 阿部康二, 山下徹

脳循環代謝 34 ( 1 ) 160 - 160 2022.10

Japanese case of Charcot-Marie-Tooth disease type 2Z with severe retinitis pigmentosa

Emi Nomura, Koh Tadokoro, Ryo Sasaki, Yumi Nakata, Yumiko Nakano, Taijun Yunoki, Mami Takemoto, Ryuta Morihara, Masahiro Ando, Hiroshi Takashima, Toru Yamashita

NEUROLOGY AND CLINICAL NEUROSCIENCE 10 ( 5 ) 266 - 268 2022.9

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY

Charcot-Marie-Tooth disease type 2Z (CMT2Z) shows highly variable clinical features. We report the first Japanese CMT2Z patient with a c.754C>T (p.R252W) substitution of the MORC2 gene, complicating severe retinitis pigmentosa. The MORC2 mutants were involved in a decrease in cell survival through induction of apoptosis. Thus, the MORC2 mutation might be involved in the degeneration of photoreceptors and the development of retinitis pigmentosa.

DOI： 10.1111/ncn3.12660

Web of Science

researchmap

A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene

Chika Matsuoka, Yuki Taira, Ryo Sasaki, Namiko Matsumoto, Koh Tadokoro, Emi Nomura, Yuko Kawahara, Mami Takemoto, Ryuta Morihara, Akihiro Hashiguchi, Hiroshi Takashima, Hidemi Takeuchi, Motoo Araki, Koji Abe, Toru Yamashita

Neurology and Clinical Neuroscience 10 ( 5 ) 252 - 254 2022.9

Publishing type：Research paper (scientific journal)

Focal and segmental areas of glomerular sclerosis (FSGS) have various subcategories. Here, we report on a 35-year-old man who suffered from Charcot-Marie-Tooth disease (CMT) with FSGS carrying the INF2 mutation (c.206 T > C, p.L69P). The INF2 mutation might cause abnormal actin filaments of the podocytes and Schwann cells, leading to CMT associated with FSGS. He successfully underwent living donor kidney transplantation from a mother with a normal INF2 gene without any serious adverse events. Following genetic testing, the identification of the INF2 mutation allows a recipient to reduce the use of immunosuppressive drugs. Genetic testing may provide a treatment plan for kidney transplantation.

DOI： 10.1111/ncn3.12651

Scopus

researchmap

A Japanese case of successful surgical resection of cerebral cavernous malformations with a CCM2 mutation

Emi Nomura, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Yumiko Nakano, Taijun Yunoki, Ryuta Morihara, Tatsuya Sasaki, Hiroyuki Akagawa, Koji Abe, Toru Yamashita

NEUROLOGY AND CLINICAL NEUROSCIENCE 2022.6

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY

Cerebral cavernous malformations (CCMs) are congenital abnormalities of cerebral vessels. Surgical resection is rarely considered for the control of epilepsy in a first seizure patient with vascular malformation. In contrast, lesions that produce repetitive or progressive symptoms should be considered for surgical resection as treatment. Herein, we report a Japanese patient with a CCM2 mutation, c.609G>A (p.K203K) substitution, who showed drug-resistant epilepsy and dramatic improvement after surgical resection.

DOI： 10.1111/ncn3.12649

Web of Science

researchmap

　 PREV - NEXT 　

< TAKEMOTO Mami >

Papers - TAKEMOTO Mami